IKNA Ikena Oncology
- 1.310
- +0.010+0.77%
Ikena Oncology News
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
PDF Version BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company"), a targeted oncology company forging new territory in patient-directed cancer treatmen
The Analyst Landscape: 4 Takes On Ikena Oncology
4 analysts have expressed a variety of opinions on Ikena Oncology (NASDAQ:IKNA) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below offers a condensed vie
Express News | HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $11 Price Target
Ikena Oncology's IK-595: A Promising Contender in the MAPK-Driven Tumor Space
Ikena Oncology's Promising Drug Pipeline Merits a Buy Rating
Ikena Oncology: Q4 Earnings Insights
Ikena Oncology (NASDAQ:IKNA) reported its Q4 earnings results on Tuesday, March 12, 2024 at 08:00 AM.Here's what investors need to know about the announcement.EarningsIkena Oncology beat estimated ear
Ikena Oncology Is Maintained at Buy by HC Wainwright & Co.
Ikena Oncology Is Maintained at Buy by HC Wainwright & Co.
Ikena Oncology's IK-930: A Promising Contender in Targeted Oncology Treatments
Express News | HC Wainwright & Co. Maintains Buy on Ikena Oncology, Maintains $11 Price Target
Ikena Oncology Q4 EPS $(0.41) Beats $(0.43) Estimate, Sales $658.00K Miss $3.14M Estimate
Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.43) by 4.65 percent. This is a 5.13 percent decrease over losses of $(0.39)
Ikena Oncology 4Q Loss/Shr $0.41 >IKNA
Ikena Oncology 4Q Loss/Shr $0.41 >IKNA
Press Release: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
PDF Version IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokineticsIK-930 clinical update planned for 2H 2024 including additional data from EHE pat
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
PDF Version BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company"), a targeted oncology company forging new territory in patient-directed cancer treatment
Ikena Oncology Announces Leadership Change and Strategic Shift
Press Release: Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug de
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
PDF Version Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertiseDr. Germa will drive clinical developme
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChina SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.2% to $2.73 during Friday's pre-market session. The company's market cap stands at $1.5 million. MediciNova (NASDAQ:MNOV) stock inc
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Ikena Oncology (IKNA) Gets a Buy From Wedbush
Analysis
Price Target
No Data
